Anteris Technologies Global Corp. (AVR)

NGM – Цена в реальном времени. Валюта: USD

6.70

+0.19 (2.92%)

При закрытии: May 12, 2026, 4:00 PM EDT

6.70

0.00 (0.00%)

До открытия: May 13, 2026, 5:29 AM EDT

Anteris Technologies Global Corp. (AVR)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Anteris Technologies Global Corp. (AVR)

Anteris Announces Results for the First Quarter of 2026

Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial

Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial

Anteris Technologies Looks Bullish If DurAVR's PARADIGM Delivers

Anteris Reports 2025 Financial Results and Provides Corporate Update

Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises

Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock

Видео

No Data

Пресс-релизы

Anteris Announces Results for the First Quarter of 2026

Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial

Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial

Anteris Reports 2025 Financial Results and Provides Corporate Update

Anteris Announces Results for the First Quarter of 2026

Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial

Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial

Anteris Technologies Looks Bullish If DurAVR's PARADIGM Delivers

Anteris Reports 2025 Financial Results and Provides Corporate Update

Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises

Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock

Видео

No Data

Пресс-релизы

Anteris Announces Results for the First Quarter of 2026

Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial

Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial

Anteris Reports 2025 Financial Results and Provides Corporate Update

Search stocks

Anteris Technologies Global Corp. (AVR)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Anteris Technologies Global Corp. (AVR)

Anteris Announces Results for the First Quarter of 2026

Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial

Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial

Anteris Technologies Looks Bullish If DurAVR's PARADIGM Delivers

Anteris Reports 2025 Financial Results and Provides Corporate Update

Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises

Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock

Видео

No Data

Пресс-релизы

Anteris Announces Results for the First Quarter of 2026

Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial

Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial

Anteris Reports 2025 Financial Results and Provides Corporate Update

Anteris Announces Results for the First Quarter of 2026

Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial

Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial

Anteris Technologies Looks Bullish If DurAVR's PARADIGM Delivers

Anteris Reports 2025 Financial Results and Provides Corporate Update

Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises

Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock

Видео

No Data

Пресс-релизы

Anteris Announces Results for the First Quarter of 2026

Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial

Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial

Anteris Reports 2025 Financial Results and Provides Corporate Update